Teva-Handok said that it has presented the exploratory endpoint results of FOCUS phase 3 clinical trials for Fremanezumab, a migraine treatment, during the 5th Congress of the European Academy of Neurology (EAN) held in Norway.
|Teva's migraine treatment Ajovy|
The FOCUS study evaluated the efficacy and safety of Fremanezumab as an agent for the prevention of migraine in adult patients who had previously had an inadequate response to two or four series of prophylactic agents.
Clinical results of Fremanezumab showed the reduced number of migraine-related days and symptoms, improved headache and quality of life, depressive symptoms, work productivity and dysfunction, and reduced use of acute headache remedies.
"The FOCUS study results demonstrate the potential of Fremanezumab in addressing the burden of migraine in this difficult-to-treat patient population," said Professor Patricia Pozo Rosich, director of the Headache Clinical Unit and Research Group at Vall d'Hebron Hospital and Institute of Research.
The team is glad to see the exploratory data being presented at EAN, which includes quality of life and disability results for patients who have a substantial daily burden due to their migraine, she added.
Teva-Handok CEO Park Sun-dong also said, "Fremanezumab will continue to reduce the number of migraine days and various migraine-related symptoms, and will strengthen its position as a preventive treatment for migraine headaches at home and abroad."